Results 91 to 100 of about 116,176 (290)

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. [PDF]

open access: yes, 2019
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or ...
Bairey, Osnat   +19 more
core   +3 more sources

Mitochondrial CircRNA CircMT‐RNR2 Safeguards Antioxidant Defense to Support Fibroblast Functions in Wound Repair

open access: yesAdvanced Science, EarlyView.
CircMT‐RNR2 promotes wound healing by enhancing fibroblast proliferation, migration, contraction, and extracellular matrix (ECM) production. It sustains mitochondrial redox balance by stabilizing the antioxidant protein PRDX3, thereby reducing ROS‐induced damage. In diabetic foot ulcers, hypoxia, hyperglycemia, and reduced FGF2 and EGF expression lower
Guanglin Niu   +13 more
wiley   +1 more source

Deregulated Levels of the NF-κB1, NF-κB2, and Rel Genes in Ukrainian Patients with Leukemia and Lymphoma in the Post-Chernobyl Period

open access: yesTurkish Journal of Hematology, 2016
INTRODUCTION: Nuclear factor kappa B (NF-κB) is an important transcription factor in cancer and NF-κB activation has been seen in angiogenesis, tumor progression, and metastasis.
Hakan Savlı   +7 more
doaj   +1 more source

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases [PDF]

open access: yes, 2017
Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors.
Berno, Tamara   +12 more
core   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

open access: yesAdvanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu   +11 more
wiley   +1 more source

Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells

open access: yesHaematologica, 2008
Background Patients with chronic lymphocytic leukemia whose cells express CD38 and ZAP-70 and utilize unmutated Ig VH region genes have a very poor prognosis. We studied whether cells expressing CD38 and ZAP-70 are more susceptible to stimulation through
Giovanna Cutrona   +11 more
doaj   +1 more source

Preleukemia: hematological disorders prior to onset of leukemia [PDF]

open access: yes, 1975
Published data on Japanese leukemia patients with a preleukemic hematological disorder were assessed. The reexamined cases were from the "Japona Centra Revuo Medicina" reported during the period from 1952 to 1971.
Hiraki, Kiyoshi   +5 more
core   +1 more source

Heparin Induces Apoptosis in Lymphocytes from B-cell Chronic Lymphocytic Leukemia

open access: yesHematology, 1998
It has been shown that glycosaminoglycans play a role in the regulation of immune response. In particular, heparin exerts an antiproliferative and apoptotic action in different cellular systems. In this study we evaluate whether heparin can also induce a naturally occurring programmed cell death in lymphocytes from B-chronic lymphocytic leukemia (B-CLL)
Vianello F.   +7 more
openaire   +4 more sources

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

open access: yesAdvanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang   +7 more
wiley   +1 more source

Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells

open access: yesHaematologica, 2013
Chronic lymphocytic leukemia is an incurable B-cell malignancy that is associated with tumor cell-mediated T-cell dysfunction. It therefore represents a challenging disease for T-cell immunotherapeutics.
Ryan Wong   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy